Technology & Platform

eFlow® Technology

In order to meet patients´ need for silent, fast and efficient delivery of aerosolised liquid drug products, PARI developed the eFlow Technology platform. A core component of all eFlow Technology nebulisers is a laser drilled, vibrating stainless steel membrane. Using a tightly controlled laser drilling process, the geometry of the holes in the membrane can be adjusted to produce aerosols with specific characteristics for optimised respiratory delivery.

All eFlow Technology nebulisers for spontaneously breathing patients utilise a patented mixing chamber with inhalation and exhalation valves. The aerosol is generated continuously into this chamber. During the inhalation phase, the aerosol is inhaled as emitted from the vibrating membrane while it is stored in the mixing chamber during the expiration phase. The stored aerosol is inhaled as a dense aerosol bolus at the onset of the following inspiration. This design reduces nebulisation time and increases delivery efficiency as the aerosol produced during the exhalation phase is largely conserved and also delivered to the patient.

eFlow® Platform

PARI’s engineers design solutions to adapt the eFlow® Technology platform to various needs of specific drug products, applications and patient populations. This includes options to tailor the nebuliser to:

  • Disease-specific breathing patterns
  • Deposition of aerosol droplets in different regions of the lungs
  • Enable supplemental oxygen during aerosol therapy
  • Diverse age groups (from pre-maturely born neonates to children, adolescents, adults and elderly patients)
  • Spontaneously breathing or mechanically ventilated patients
  • Upper or lower respiratory tract drug delivery
  • Systemic drug delivery via the lungs


Overview eFlow® Technology platform

    Video about the eFlow® Technology nebuliser system

    Watch this video to learn about the eFlow® Technology nebuliser system (Open System) and its unique components.

    Aerosolisation of a broad variety of formulations

    Both the eFlow® and Vibrent® Technology can be adjusted to successfully nebulise a variety of molecules and formulations with a broad range of fill volumes and physicochemical properties, including:

    • Small molecules (e.g. Glycopyrrolate, Tobramycin, Levofloxacin and others)
    • Protein formulations (e.g. Alpha-1-Antitrypsin)
    • Peptides (e.g. POL6014),
    • Oligonucleotides (e.g. Eluforsen QR-010)
    • Suspensions including liposomal formulations (e.g. Liposomal Amikacin, Liposomal Cyclosporine A)

    Contact us

    Do you have any questions about our technology, partnering approach and services?

    Please contact us!
    eFlow-partneringpari.com